Redhill Biopharma Ltd. ADR [RDHL] stock prices are up 6.14% to $0.60 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RDHL shares have gain 13.49% over the last week, with a monthly amount glided 0.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, RedHill’s Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis – New Publication. In a post published today on Yahoo Finance, The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation .
From an analyst’s perspective:
Redhill Biopharma Ltd. ADR [NASDAQ: RDHL] stock has seen the most recent analyst activity on August 31, 2021, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $22. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 18, 2021, and set its price target to $23. On September 11, 2020, BTIG Research initiated with a Buy rating. WBB Securities upgraded its rating to a Strong Buy. WBB Securities upgraded its rating to a Buy. Nomura started tracking with a Buy rating for this stock on January 26, 2018, and assigned it a price target of $18. In a note dated October 06, 2017, Seaport Global Securities initiated an Buy rating and provided a target price of $19 on this stock.
The stock price of Redhill Biopharma Ltd. ADR [RDHL] has been fluctuating between $0.26 and $9.21 over the past year. Redhill Biopharma Ltd. ADR [NASDAQ: RDHL] shares were valued at $0.60 at the most recent close of the market.
Analyzing the RDHL fundamentals
The Redhill Biopharma Ltd. ADR [NASDAQ:RDHL] reported sales of 35.52M for trailing twelve months, representing a drop of -90.21%. Gross Profit Margin for this corporation currently stands at 0.43% with Operating Profit Margin at 0.82%, Pretax Profit Margin comes in at 0.32%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is 0.49 and Total Capital is 4.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5620 points at the first support level, and at 0.5240 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6309, and for the 2nd resistance point, it is at 0.6618.
Ratios To Look Out For
It’s worth pointing out that Redhill Biopharma Ltd. ADR [NASDAQ:RDHL]’s Current Ratio is 0.96. On the other hand, the Quick Ratio is 0.78, and the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 0.50, the price to book ratio is 0.68.
